The use of 2 antibiotic regimens in aggressive periodontitis: Comparison of changes in clinical parameters and gingival crevicular fluid biomarkers

Quintessence International

Volumn 39, Issue 10, 2008, Pages 811-819

  Machtei, Eli E ^a,b   Younis, Mahmoud N ^c  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Rambam Medical Center ^*

Author keywords

Aggressive periodontitis; Antibiotic regimen; Clinical attachment level; Cytokines; Gingival crevicular fluid; Treatment

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; DOXYCYCLINE; INTERLEUKIN 1BETA; METRONIDAZOLE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; GINGIVITIS; HUMAN; IMMUNOLOGY; MALE; MOUTH HYGIENE; PERIODONTICS; PERIODONTITIS; PREVENTIVE DENTISTRY; TOOTH PLAQUE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGGRESSIVE PERIODONTITIS; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; DENTAL PLAQUE INDEX; DENTAL SCALING; DINOPROSTONE; DOXYCYCLINE; DRUG COMBINATIONS; FEMALE; GINGIVAL CREVICULAR FLUID; HUMANS; INTERLEUKIN-1BETA; MALE; METRONIDAZOLE; ORAL HYGIENE; PERIODONTAL INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 54449087992     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Williams RC. Periodontal disease. N Engl J Med 1990; 322:373-382.
2. Genco RJ. Host response in periodontal disease: Current concepts. J Periodontol 1992;63:338-355.
3. Offenbacher S. Periodontal diseases: Pathogenesis. Ann Periodontol 1996;1:821-878.
4. Alexander MB, Damoulis PD.The role of cytokines in the pathogenesis of periodontal disease. Curr Opin Periodontol 1994;2:39-53.
5. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998;9:248-266.
6. Bendtzen K. Clinical significance of cytokines: Natural and therapeutic regulation. Semin Clin Immunol 1991;3:5-13.
7. Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic and endocrine diseases. Autoimmunity 1989;2:177-189.
8. Gowen M, Wood DO, Ihrie EJ, McGuire MKB, Russell RG. An interleukin 1-like factor stimulates bone resorption in vitro. Nature 1983;306:378-380.
9. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1986;319:516-518.
10. Stashenko P, Dewhirst FE, Peros WJ, Kent RL, Ago JM. Synergistic interaction between IL-1, tumor recrosis factor, and lymphotoxin in bone resorption. J Immunol 1987;138:1464-1468.
11. Mølvig J, Baek L, Christensen P, et al. Endotoxin-stimulated human monocyte secretion of interleukin-1, tumor necrosis factor-α, and prostaglandin E2 shows stable interindividual differences. Scand J Immunol 1988;27:705-716.
12. McFarlane CG, Reynolds JJ, Meikle MC. The release of interleukin-1, tumor necrosis factor and interferon A by cultured peripheral blood mononuclear cells from patients with periodontitis. J Periodontal Res 1990;26:207-214.
13. Kjeldsen M, Holmstrup P, Lindemann RA, Beudtzen K. Bacterial-stimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. J Periodontol 1995;66: 139-144.
14. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin 1 receptor antagonism gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1380-1385.
15. Offenbacher S, Sosckolne WA, Collins JG. Prostaglandins and other eicosanoids in gingival crevicular fluid as markers of periodontal disease susceptibility and activity. In: Johnson NW (ed). Risk Markers for Oral Diseases, vol. 3. Cambridge: Cambridge University Press, 1991:313-337.
16. Offenbacher S, Odle BM, Gray RC, van Dyke TE. Crevicular fluid prostaglandin E levels as a measure of the periodontal disease status of adult and juvenile periodontitis patients. J Periodontal Res 1984; 19:1-13.
17. Lu H, Wang M, Gunsolley JC, Schenkein HA, Tew JG. Serum immunoglobulin G subclass concentrations in periodontally healthy and diseased individuals, Infec Immun 1994;62:1677-1682.
18. Tanaka S, Barbour SE, Best AM, Schenkein HA, Tew JG. Prostaglandin E2-mediated regulation of immunoglobulin G2 via interferon gamma. J Periodontol 2003;74:771-779.
19. Herrera D, Sanz M, Jepsen S, Needleman I, Roldán S. A systematic review on the effect of systemic antimicrobials as an adjunct to scaling and root planning in periodontitis patients. J Clin Periodontol 2002;29(suppl 3):136-162.
20. Kaner D, Christan C, Dietrich T, Bernimoulin JR Kleber BM, Friedmann A. Timing affects the clinical outcome of adjunctive systemic antibiotic therapy for generalized aggressive periodontitis. J Periodontol 2007;78:1201-1208.
21. Guerrero A, Echeverría JJ, Tonetti MS. Incomplete adherence to an adjunctive systemic antibiotic regimen decreases clinical outcomes in generalized aggressive periodontitis patients: a pilot retrospective study. J Clin Periodontol 2007;34:897-902.
22. Slots J, Rosling BG. Suppression of the periodontopathic microflora in localized juvenile periodontitis by systemic tetracycline. J Clin Periodontol 1983;10: 465-486.
23. Lindhe J, Liljenberg B. Treatment of localized juvenile periodontitis. Results after 5 years. J Clin Periodontol 1984;11:399-410.
24. Kornmen KS, Robertson PB. Clinical and microbiological evaluation of therapy for juvenile periodontitis. J Periodontol 1985;56:443-446.
25. Mandell RL, Socransky SS. Microbiological and clinical effects of surgery plus doxycycline on juvenile periodontitis. J Periodontol 1988;59:373-379.
26. Novak MJ, Poison AM, Adair SM. Tetracycline therapy in patients with early juvenile periodontitis. J Periodontol 1988;59:366-372.
27. Gordon JM, Walker CB, Murphy JC, Goodson JM, Socransky SS. Tetracyclines: Levels achievable in gingival crevice fluid and in vitro effect on subgingival organisms. Part 1. Concentration in crevicular fluid after repeated doses. J Periodontol 1981;52: 609-612.
28. Pascale D, Gordon J, Lamster I, Mann P, Seiger M, Arndt W. Concentration of doxycycline in human gingival fluid. J Clin Periodontol 1986;13:841-844.
29. Bornhart ER. Physician's Desk Reference, 43rd edition, Oradell, New Jersey: Medical Economics Company, 1989:1626-1627.
30. Kucers A, Bennet, NMcK. The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis, ed 2. London: William Heinemann Medical Books, 1977: 381-416.
31. Hinton NA. The effect of oral tetracycline HCI and doxycycline on the intestinal flora. Curr Ther Res Clin Exp 1970;12:341-352.
32. Golub LM, Ramamurthy N, McNamara TF. Tetracycline inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. J Periodontal Res 1984;19:651-655.
33. Golub LM, Wolff M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985;20:12-23.
34. Gomes BC, Golub LM, Ramamurthy NS. Tetracyclines inhibit parathyroid hormone-induced bone résorption in organ culture. Experientia 1984; 40:1273-1275
35. Giedrys-Leeper E., Selipsky H, Williams BL. Effect of short-term administration of metronidazole on the subgingival microflora. J Clin Periodontol 1985;12: 797-814.
36. Britt MR, Pohlod DJ. Serum and crevicular fluid concentrations after a single oral dose of metronidazole. J Periodontol 1986;57:104-107.
37. Sutter VL, Jones JM, Ghoniem AT. Antimicrobial susceptibilities of bacteria associated with periodontal disease. Antimicrob Agents Chemother 1983;23: 483-486.
38. Walker CB, Gordon JM, Socransky SS. Antibiotic susceptibility testing on subgingival plaque samples. J Clin Periodontol 1983;10:422-432.
39. Dörfer CE. Antimicrobials for the treatment of aggressive periodontitis. Oral Dis 2003;9(suppl 1): 51-53.
40. van Winkelhoff AJ, Tijhot CJ, de Graaff, J. Microbiological and clinical results of metronidazole plus amoxicillin therapy in actinomyce actinomycetemcomitans associated periodontitis. J Periodontol 1992;63:52-57.
41. Winkel EG, Van Winkelhoff AJ, Timmerman MF, Vangsted T, van der Velden U. Effects of metronidazole in patients with "refractory" periodontitis associated with Bacteroides forsythus. J Clin Periodontol 1997;24:573-579.
42. Berglundh T, Krok L, Liljenberg B, Westfelt E, Serino G, Lindhe J. The use of metronidazole and amoxicillin in the treatment of advanced periodontal disease. A prospective, controlled clinical trial. J Clin Periodontol 1998;25:354-362.
43. López NJ, Gamonal JA. Effects of metronidazole plus amoxicillin in progressive untreated adult periodontitis: Results of a single 1-week course after 2 and 4 months. J Periodontol 1998;69:1291-1298.
44. Ramfjord SP. Indices for prevalence and indices of periodontal disease. J Periodontol 1959;30:51-59.
45. Gunsolley JC, Zambon JJ, Mellott CA, Brooks CN, Kaugars CC. Periodontal therapy in young adults with severe generalized periodontitis. J Periodontol 1994;65:268-273.
46. Darby IB, Hodge PJ, Riggio MP, Kinane DF. Clinical and microbiological effect of scaling and root planing in smoker and nonsmoker chronic and aggressive periodontitis patients. J Clin Periodontol 2005;32:200-206.
47. Kamma JJ, Giannopoulou C, Vasdekis VG, Mombelli A. Cytokine profile in gingival crevicular fluid of aggressive periodontitis: influence of smoking and stress. J Clin Periodontol 2004;31:894-902.
48. Giannopoulou C, Kamma JJ, Mombelli A. Effect of inflammation, smoking, and stress on gingival crevicular fluid cytokine level. J Clin Periodontol 2003;30:145-153.
49. Nakashima K, Giannopoulou C, Andersen E, et al. A longitudinal study of various crevicular fluid components as markers of periodontal disease activity. J Clin Periodontol 1996;23:832-838.
50. Eley BM, Cox SW. Cathepsin B/L-, elastase-, tryptase-, trypsin and dipeptidyl peptidase IV activities in gingival crevicular fluid: Correlation with clinical parameters in untreated chronic periodontitis patients. J Periodont Res 1992;27:62-69.
51. Engebretson SP, Grbic JT, Singer R, Lamster IB. GCF IL-1beta profiles in periodontal disease. J Clin Periodontol 2002;29:48-53.
52. Genco RJ, Christersson LA, Zambon JJ. Juvenile periodontitis. Int Dent J 1986;36:168-176.
53. Hou LT, Liu CM, Rossomando EF. Crevicular interleukin-1 beta in moderate and severe periodontitis patients and the effect of phase I periodontal treatment. J Clin Periodontol 1995;22:162-167.
54. Reinhardt RA, Masada MP, Johnson GK, DuBois LM, Seymour GJ, Allison AC. IL-1 in gingival crevicular fluid following closed root planing and papillary flap debridement. J Clin Periodontol 1993;20: 514-519.
55. Masada MP, Persson R, Kenney JS, Lee SW, Page RC, Allison AC. Measurement of interleukin-1α and IL-1β in gingival crevicular fluid: Implications for the pathogenesis of periodontal disease. J Periodont Res 1990;25:156-163.
56. Offenbacher S, Collins JG, Yalda B, Haradon G. Role of prostaglandins in high risk periodontitis patients. In: Genco RJ, Hamada S, Lehner T, Mergenhagen S (eds). Molecular Pathogenesis of Periodontal Disease. Washington, DC: ASM Press, 1994:203-214.
57. Ciancio SG. Systemic medications: clinical significance in periodontics. J Clin Periodontol 2002; 29(suppl 2):17-21.
58. Slots J, Jorgensen MG. Effective, safe, practical and affordable periodontal antimicrobial therapy: Where are we going, and are we there yet? Periodontol 2000 2002;28:298-312.
59. Slots J, Ting M. Systemic antibiotics in the treatment of periodontal disease. Periodontol 2000 2002;28:106-176.
60. Walker C, Karpinia K. Rationale for use of antibiotics in periodontics. J Periodontol 2002;73:1188-1196.
61. Lang NP, Bartold PM, Cullinan M, et al. Consensus report: Aggressive periodontitis. Ann Periodontol 1999;4:53.
62. Slots J, Rosling BG. Suppression of the periodontopathic microflora in localized juvenile periodontitis by systemic tetracycline. J Clin Periodontol 1983;10: 465-486.
63. Zambon JJ, Christersson LA, Genco RJ. Diagnosis and treatment of localized juvenile periodontitis. J Am Dent Assoc 1986;113:295-299.
64. Slots J, Rams TE. Antibiotics in periodontal therapy: Advantages and disadvantages. J Clin Periodontol 1990;17:479-493.
65. Hawkey PM. The origins and molecular basis of antibiotic resistance. Br Med J 1998;317:657-660.
66. Buchmann R, Müller RF, Van Dyke TE, Lange DE. Change of antibiotic susceptibility following periodontal therapy. A pilot study in aggressive periodontal disease. J Clin Periodontol 2003;30:222-229.